BeiGene's Brukinsa Fails In Head-To-Head But Hope Remains For Rare Indication
Signs Of Benefit Vs Imbruvica
Executive Summary
Days after bagging a US approval for its first global new drug, BeiGene was dealt a blow as its BTK inhibitor Brukinsa showed no significant superiority over class leader Imbruvica in Waldenström's macroglobulinemia, although the Chinese company remains hopeful for a possible approval.
You may also be interested in...
After US Approval, BeiGene Set To Gain Sixth PD-1 Green Light In China
Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.
Keeping Track Of User Fee Decisions And Filings: Adakveo, Brukinsa And Fetroja Mark Massive Week Of Novel Approvals
The latest news on US FDA user fee decisions and submissions to the agency.
China's New Hong Kong Security Law To Derail Biotech IPOs?
A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.
Need a specific report? 1000+ reports available
Buy Reports